Investors

/Investors
Investors 2019-12-05T09:58:15+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

5.23
-0.09 (-1.69%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :24,350
Date :12-13-2019

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Appoints Dr. Arie Mayer to Board of Directors

December 5th, 2019|Comments Off on Oramed Appoints Dr. Arie Mayer to Board of Directors

Dr. Mayer is the current Managing Director and Chairman of the Board of Merck Life Science Israel NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical [...]

Oramed to Present a Scientific Poster at International Diabetes Federation Congress

December 2nd, 2019|Comments Off on Oramed to Present a Scientific Poster at International Diabetes Federation Congress

NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at [...]

Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

November 21st, 2019|Comments Off on Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the [...]

Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

November 19th, 2019|Comments Off on Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

ORMD-0801 dosed once daily reduced A1C by 0.60% compared to only a 0.06% reduction by placebo ORMD-0801 improves metabolic control as evidenced by significant reduction in A1C levels in patients with type 2 diabetes inadequately [...]